Form 8-K - Current report:
SEC Accession No. 0001193125-24-207129
Filing Date
2024-08-26
Accepted
2024-08-26 16:39:30
Documents
14
Period of Report
2024-08-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d834963d8k.htm   iXBRL 8-K 41804
  Complete submission text file 0001193125-24-207129.txt   201761

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA achv-20240820.xsd EX-101.SCH 2790
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20240820_def.xml EX-101.DEF 13501
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20240820_lab.xml EX-101.LAB 22373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20240820_pre.xml EX-101.PRE 14307
16 EXTRACTED XBRL INSTANCE DOCUMENT d834963d8k_htm.xml XML 5336
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 241241951
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)